TY - JOUR
T1 - Brugada syndrome
T2 - Recent advances and controversies
AU - Antzelevitch, Charles
AU - Nof, Eyal
N1 - Funding Information:
This article was supported by grant HL47678 from the National Heart, Lung, and Blood Institute and New York State and Florida Grand Lodges F. & A. M. Eyal Nof was supported by fellowship grants from Biotronik and the American Physicians Fellowship for Medicine in Israel. No other potential conflicts of interest relevant to this article were reported.
PY - 2008
Y1 - 2008
N2 - The Brugada syndrome, first described as a new clinical entity in 1992, is widely recognized today as a form of inherited sudden cardiac arrest. The past 16 years witnessed a progressive increase in the number of reported cases and a dramatic proliferation of articles serving to define the clinical, genetic, cellular, ionic, and molecular aspects of the disease. This article provides a brief overview of recent advances in our understanding of the clinical presentation and molecular and cellular mechanisms and an update of existing controversies.
AB - The Brugada syndrome, first described as a new clinical entity in 1992, is widely recognized today as a form of inherited sudden cardiac arrest. The past 16 years witnessed a progressive increase in the number of reported cases and a dramatic proliferation of articles serving to define the clinical, genetic, cellular, ionic, and molecular aspects of the disease. This article provides a brief overview of recent advances in our understanding of the clinical presentation and molecular and cellular mechanisms and an update of existing controversies.
UR - http://www.scopus.com/inward/record.url?scp=58149109872&partnerID=8YFLogxK
U2 - 10.1007/s11886-008-0060-y
DO - 10.1007/s11886-008-0060-y
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 18715534
AN - SCOPUS:58149109872
SN - 1523-3782
VL - 10
SP - 376
EP - 383
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 5
ER -
